Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by the increased production of monoclonal immunoglobulin. Patients with MM are at high risk of suffering from disease-related complications. Osteolytic bone disease is one of the most common disease-related complications, resulting in chronic pain and skeletal pathologies that contribute significantly to high morbidity and mortality rates among MM patients. In addition to standard anti-MM therapy, management of disease-related sequelae is integral to improving quality of life in MM patients. Bisphosphates have long been the mainstay treatment for patients with myeloma bone disease (MBD) due to their ability to reduce the incidence of skeletal-related adverse events. However, in recent years, a deeper understanding of the complex biology and pathophysiology associated with myeloma bone disease has led to the development of novel therapies that have the potential to improve MM patient management and outcomes. This narrative review uses the most recent extant publications to review all such advancements. It aims to summarize evidence-based strategies for the management of myeloma bone disease and therapy-associated adverse events whilst highlighting current guidelines on optimal bisphosphonate use and providing an overview of promising new agents currently in clinical development.
多发性骨髓瘤（MM）是一种无法治愈的浆细胞恶性肿瘤，其特征是单克隆免疫球蛋白的过度产生。MM患者面临较高的疾病相关并发症风险。溶骨性骨病是最常见的疾病相关并发症之一，可导致慢性疼痛和骨骼病变，显著增加MM患者的发病率和死亡率。除标准抗MM治疗外，疾病相关后遗症的管理对于改善MM患者生活质量至关重要。双膦酸盐类药物因其能降低骨骼相关不良事件发生率，长期以来一直是骨髓瘤骨病（MBD）的主要治疗手段。然而近年来，随着对骨髓瘤骨病复杂生物学和病理生理学机制的深入理解，新型疗法得以开发，这些疗法有望改善MM患者的治疗管理和临床结局。本叙述性综述基于最新现有文献，系统梳理了该领域的所有进展，旨在总结骨髓瘤骨病及治疗相关不良事件的循证管理策略，重点阐述当前关于双膦酸盐优化使用的指南，并对处于临床开发阶段的潜力新药进行概述。
Advances in Supportive Care for Multiple Myeloma-Related Bone Disease—A Review
肿瘤(癌症)患者之家